MedPath

Mitsubishi Tanabe Pharma America, Inc.

Mitsubishi Tanabe Pharma America, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2015-01-01
Employees
101
Market Cap
-
Website
http://www.mt-pharma-america.com

Clinical Trials

28

Active:4
Completed:18

Trial Phases

3 Phases

Phase 1:14
Phase 2:6
Phase 3:7

Drug Approvals

2

FDA:2

Drug Approvals

RADICAVA

Approval Date
Dec 7, 2023
FDA

Exservan

Approval Date
Dec 21, 2022
FDA

Clinical Trials

Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials

Phase 1
14 (51.9%)
Phase 3
7 (25.9%)
Phase 2
6 (22.2%)

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Non-small Cell Lung Cancer (NSCLC)
Esophageal Cancer
Gastric Cancer
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Breast Cancer
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Interventions
First Posted Date
2025-04-24
Last Posted Date
2025-07-20
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
27
Registration Number
NCT06943521
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

Phase 3
Active, not recruiting
Conditions
Erythropoietic Protoporphyria (EPP)
X-Linked Protoporphyria (XLP)
Interventions
Drug: Placebo
First Posted Date
2023-11-22
Last Posted Date
2025-04-18
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
165
Registration Number
NCT06144840
Locations
🇺🇸

Marvel Clinical Research, LLC, Huntington Beach, California, United States

🇺🇸

University of California at San Francisco, San Francisco, California, United States

🇺🇸

University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States

and more 33 locations

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2022-02-15
Last Posted Date
2023-05-15
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
29
Registration Number
NCT05241535
Locations
🇺🇸

Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States

🇺🇸

Dallas Clinical Research Unit, Dallas, Texas, United States

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Phase 3
Terminated
Conditions
ALS
Interventions
Drug: Placebo
First Posted Date
2021-12-09
Last Posted Date
2025-03-27
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
202
Registration Number
NCT05151471
Locations
🇺🇸

Woodland Research Northwest, LLC, Rogers, Arkansas, United States

🇺🇸

UF Health Cancer Center/Clinical Trials Office, Gainesville, Florida, United States

🇺🇸

Emory University - School of Medicine, Atlanta, Georgia, United States

and more 34 locations

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Phase 3
Recruiting
Conditions
EPP
XLP
Interventions
First Posted Date
2021-08-16
Last Posted Date
2025-04-22
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
301
Registration Number
NCT05005975
Locations
🇺🇸

University of California at San Francisco - CSF Porphyria Center, San Francisco, California, United States

🇺🇸

University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 48 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.